NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/31/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,338.27 mln
Float28.15 mln
Earnings Date08/13/2026
1-Year Forecast
34.38
Exceptional upside
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-44.11
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Aktis Oncology is a Boston-based clinical-stage company focused on developing radioactive drug treatments that target and destroy solid tumor cancers. Its two lead candidates use a miniprotein platform to deliver a radioactive element directly to cancer cells expressing specific proteins, with one currently in Phase 1b trials across multiple cancer types including bladder, breast, and lung cancer. The company works with several research and industry partners, including Eli Lilly, to advance its pipeline.
